E. St Rose

发表

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

E. Kerwin, F. Martinez, K. Rabe, 2017, Respiratory Research.

A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.

F. Martinez, R. Rodríguez-Roisín, D. Tashkin, 2016, Respiratory medicine.

Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD

W. De Backer, C. Van Holsbeke, G. Leemans, 2020, Therapeutic advances in respiratory disease.

A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.

Greg Tardie, D. Quinn, C. Reisner, 2014, Respiratory medicine.

A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.

P. Dorinsky, J. Wedzicha, F. Martinez, 2019, Respiratory medicine.

Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study.

F. Martinez, S. Rennard, N. Hanania, 2017, Chronic obstructive pulmonary diseases.

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

J. Wedzicha, F. Martinez, K. Rabe, 2020, American journal of respiratory and critical care medicine.

Synthesis and activity of 2-(sulfonamido)methyl-carbapenems: discovery of a novel, anti-MRSA 1,8-naphthosultam pharmacophore.

J. Heck, R. Wilkening, K. J. Wildonger, 1999, Bioorganic & medicinal chemistry letters.

Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.

J. Heck, S. T. Waddell, R. Wilkening, 1999, Bioorganic & medicinal chemistry letters.

The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.

P. Dorinsky, P. DePetrillo, C. Reisner, 2018, Pulmonary pharmacology & therapeutics.

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD

E. Kerwin, R. Rodríguez-Roisín, L. Fabbri, 2016, Respiratory Research.

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.

P. Dorinsky, J. Wedzicha, F. Martinez, 2020, The New England journal of medicine.

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD

G. Feldman, C. Reisner, G. Gottschlich, 2017, Respiratory Research.

An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease

G. Feldman, C. Reisner, P. Mack, 2019, Journal of aerosol medicine and pulmonary drug delivery.

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD

E. Kerwin, C. Reisner, P. Darken, 2018, International journal of chronic obstructive pulmonary disease.

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD

C. Reisner, A. Maes, S. Siddiqui, 2018, International journal of chronic obstructive pulmonary disease.

A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD

E. Kerwin, C. Reisner, C. Kollar, 2018, Respiratory Research.